132 related articles for article (PubMed ID: 37303659)
1. Comparison of the clinical efficacy of donafinil and lenvatinib in the treatment of intermediate and advanced hepatocellular carcinoma.
He Q; Guo M; Ya Y; Huang J; Liu A; Jing W
Am J Transl Res; 2023; 15(5):3579-3585. PubMed ID: 37303659
[TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma.
Xu R; Ji X; Pei X; Yu Y
Am J Transl Res; 2023; 15(2):1117-1128. PubMed ID: 36915764
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Meng R; Zhang X; Zhou T; Luo M; Qiu Y
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1079-1086. PubMed ID: 35579405
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor.
Xie QY; Huang LP; Gao FW; Liu DQ; Wang X; Jiang KY; Gong J; Zhao X; Gao BJ; Lei ZH
Front Pharmacol; 2022; 13():965770. PubMed ID: 36339553
[No Abstract] [Full Text] [Related]
6. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience.
Zhang S; Yang G; Song R; Wang W; Meng F; Yin D; Wang J; Zhang S; Cai W; Liu Y; Luo D; Wang J; Liu L
Ther Adv Med Oncol; 2024; 16():17588359241258394. PubMed ID: 38882444
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
[TBL] [Abstract][Full Text] [Related]
9. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
[No Abstract] [Full Text] [Related]
10. The efficacy and adverse effects of nivolumab and lenvatinib in the treatment of advanced hepatocellular carcinoma.
Wen S; Zeng J; Zhong L; Ye J; Lai X
Cell Mol Biol (Noisy-le-grand); 2022 Nov; 68(11):53-57. PubMed ID: 37114307
[TBL] [Abstract][Full Text] [Related]
11. Real-World Lenvatinib
Kuo YH; Lu SN; Chen YY; Kee KM; Yen YH; Hung CH; Hu TH; Chen CH; Wang JH
Front Oncol; 2021; 11():737767. PubMed ID: 34760699
[TBL] [Abstract][Full Text] [Related]
12. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Xu Y; Fu S; Shang K; Zeng J; Mao Y
Front Oncol; 2022; 12():958869. PubMed ID: 36176403
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.
Guan H; Wang C; Zhao Z; Han S
Adv Ther; 2022 Jul; 39(7):3334-3346. PubMed ID: 35644019
[TBL] [Abstract][Full Text] [Related]
14. Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy.
Li X; Wang J; Ding X; Xu Y; Yu M; Wu H; Deng N; Li W; Chen J
Front Pharmacol; 2022; 13():1032881. PubMed ID: 36703739
[No Abstract] [Full Text] [Related]
15. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.
Fan W; Zhu B; Yue S; Zheng X; Zou X; Li F; Qiao L; Wu Y; Xue M; Wang H; Tang Y; Li J
Cancer Med; 2023 Jan; 12(1):61-72. PubMed ID: 35698292
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
Liu Y; Qiao Y; Zhou M; Guo J; Lin Y; Li W; An C; Li C
Cancer Med; 2023 Mar; 12(5):5436-5449. PubMed ID: 36254376
[TBL] [Abstract][Full Text] [Related]
18. Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib.
Liu B; Shang X; Shi JY; Cui GZ; Li X; Wang NY
Front Oncol; 2022; 12():807189. PubMed ID: 35251977
[TBL] [Abstract][Full Text] [Related]
19. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
